Long-term outcomes of a case-control lung transplant cohort after SARS-CoV-2 infection
Open Access
- 21 May 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 4, 1583919
Abstract
Background: Respiratory viruses can impact the allograft function in lung transplant recipients, but it is unknown if this occurs with SARS-CoV-2 infection. We studied the long-term outcomes of lung transplant recipients infected with SARS-CoV-2.Methods: This single-center retrospective study compared lung transplant recipients with SARS-CoV-2 between June 2020 and April 2021 with a matched control group. Within the SARS-CoV-2 cohort, univariable associations between clinical factors and outcomes were tested. Changes in pulmonary function tests were analyzed. Primary endpoints included acute cellular rejection and all-cause mortality within 12 months.Results: Fifty-three lung transplant recipients were infected with SARS-CoV-2. The median age was 64 years. 29 (54.7%) were managed outpatient, and 24 (45.3%) required hospitalization, with 13 intensive care unit admissions. All-cause mortality was 24.5%. Within the SARS-CoV-2 cohort, older age was significantly associated with all-cause mortality (p-value 0.017) as was ICU admission (p = 0.009) and an A1C > 6.5 (p = 0.033). The mean change in FEV1 was −1.1% at 3 months with minimal change at 6 and 12 months (−2.6% and −1% respectively), all compared to baseline. Acute cellular rejection was identified in 13.7% of the SARS-CoV-2 cohort compared to 11.8% in the matched control group; it was not significantly associated with the infection status (p = 0.706). However, all-cause mortality was significantly associated with infection status (p = 0.019).Conclusion: Long-term outcomes of SARS-CoV-2 in lung transplant recipients are widely variable. Within the SARS-CoV-2 cohort, all-cause mortality was 24.5%, and older age was significantly associated with mortality. We did not observe significant declines in FEV1 in this group.Keywords
This publication has 24 references indexed in Scilit:
- Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future VaccinationCNS Drugs, 2020
- Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort StudyClinical Infectious Diseases, 2020
- COVID-19 in solid organ transplant recipients: Initial report from the US epicenterAmerican Journal of Transplantation, 2020
- Graft Loss and CLAD-Onset Is Hastened by Viral Pneumonia After Lung TransplantationTransplantation, 2016
- Symptomatic Respiratory Virus Infection and Chronic Lung Allograft DysfunctionClinical Infectious Diseases, 2015
- Respiratory Viruses in Lung Transplant Recipients: A Critical Review and Pooled Analysis of Clinical StudiesAmerican Journal of Transplantation, 2011
- Upper and Lower Respiratory Tract Viral Infections and Acute Graft Rejection in Lung Transplant RecipientsClinical Infectious Diseases, 2010
- Spirometric Assessment of Lung Transplant Patients: One Year Follow-UpClinics, 2009
- Respiratory Viral Infections Are a Distinct Risk for Bronchiolitis Obliterans Syndrome and DeathAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Spirometry Values in Stable Lung Transplant RecipientsAmerican Journal of Respiratory and Critical Care Medicine, 1997